迈威生物(688062.SH)：注射用7MW4911临床试验申请获FDA许可

Group 1 - The core point of the article is that Maiwei Biotech (688062.SH) has received a Clinical Study Continuation Notification from the FDA, allowing the clinical trial application for the injectable 7MW4911 to proceed [1] - The clinical trial will focus on the safety, pharmacokinetics, and efficacy of 7MW4911 in patients with advanced colorectal cancer and other advanced gastrointestinal tumors [1]